Featured Participatory Project: GlaxoSmithKline, the Diabetes Drug Avandia and Dr. John Buse
Published on PR Watch (https://www.prwatch.org)

Home > Featured Participatory Project: GlaxoSmithKline, the Diabetes Drug Avandia and Dr. John Buse

Featured Participatory Project: GlaxoSmithKline, the Diabetes Drug Avandia and Dr. John Buse [1]

Submitted by Bob Burton [2] on

The United States Senate Committee on Finance has released a damning staff report [3] titled The Intimidation of Dr. John Buse and the Diabetes Drug Avandia. The report reviews how in 1999 SmithKline Beecham, known after the merger with Glaxo Wellcome as GlaxoSmithKline [4], reacted when Buse, a professor of medicine at the University of North Carolina, raised concerns about the potential for increased heart attacks associated with Avandia [5]. Internal company documents, the report states, "reveal what appears to be an orchestrated plan to stifle the opinion" of Buse, in part to reassure stockmarket analysts. The report provides a powerful case study of an attempt by a corporation to stifle scientific dissent. If you would like to help build a SourceWatch article on this, the instructions are here [6]. If this is your first time editing on SourceWatch, you can register here [7], and learn more about adding information to the site here [8], here [9] and here [10]. Have fun, and thanks for your help!

Main Source: 
United States Senate Committee on Finance, November 2007 [3]
Topics: 
Crisis Management [11]
Corporate Social Responsibility [12]
Issue Management [13]
U.S. Congress [14]
Corporations [15]
Health [16]
Lobbying [17]
Marketing [18]
Pharmaceuticals [19]
Public Relations [20]
Science [21]
Secrecy [22]
U.S. Government [23]

More

Source URL: https://www.prwatch.org/spin/2007/11/6738/featured-participatory-project-glaxosmithkline-diabetes-drug-avandia-and-dr-john-b

Links
[1] https://www.prwatch.org/spin/2007/11/6738/featured-participatory-project-glaxosmithkline-diabetes-drug-avandia-and-dr-john-b
[2] https://www.prwatch.org/users/7/bob-burton
[3] http://finance.senate.gov/press/Bpress/2007press/prb111507a.pdf
[4] https://www.sourcewatch.org/index.php/GlaxoSmithKline
[5] https://www.sourcewatch.org/index.php/Avandia
[6] https://www.sourcewatch.org/index.php/GlaxoSmithKline,_the_Diabetes_Drug_Avandia_and_The_Intimidation_of_Dr._John_Buse
[7] https://www.prwatch.org/user/register
[8] https://www.sourcewatch.org/index.php/SourceWatch:Contributing
[9] https://www.sourcewatch.org/index.php/SourceWatch:About
[10] https://www.sourcewatch.org/index.php/SourceWatch:References
[11] https://www.prwatch.org/topics/public-relations/crisis-management
[12] https://www.prwatch.org/topics/corporations/corporate-social-responsibility
[13] https://www.prwatch.org/topics/public-relations/issue-management
[14] https://www.prwatch.org/topics/us-government/us-congress
[15] https://www.prwatch.org/topics/corporations
[16] https://www.prwatch.org/topics/health
[17] https://www.prwatch.org/topics/lobbying
[18] https://www.prwatch.org/topics/marketing
[19] https://www.prwatch.org/topics/pharmaceuticals
[20] https://www.prwatch.org/topics/public-relations
[21] https://www.prwatch.org/topics/science
[22] https://www.prwatch.org/topics/secrecy
[23] https://www.prwatch.org/topics/us-government